Medicina clinica · 2026
Inflammatory myopathies with anti-TIF1γ antibodies and their association with neoplasms: a study of a series of 28 cases.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gutiérrez Baena Ana María, Mir Castro María Carlota, Verdaguer Faja Guillem, Morales Osorio Leidy Johana, Garrigasait Vilaseca Vanesa
Аннотация
BACKGROUND AND OBJECTIVE: To describe the clinical, immunological, and evolutionary profile of patients with anti-TIF1γ-positive inflammatory myopathy and to analyze its association with neoplasms.
MATERIALS AND METHODS: Retrospective study of patients with inflammatory myopathy and positive anti-TIF1γ antibodies treated at a tertiary care hospital (2012-2024). Sociodemographic variables, clinical manifestations, immunological profile, presence and type of neoplasm, treatment, and evolution were collected.
RESULTS: Twenty-eight patients were analyzed (mean age 63 years [31-88], 68% women). They were followed for a period of 5 years. Typical cutaneous manifestations predominated (61%), followed by proximal muscle weakness (61%) and dysphagia (32%), without significant pulmonary involvement. 54% presented with elevated CPK. ANA was positive in 71.4%; 57.1% presented myositis-associated antibodies and 25% other myositis-specific antibodies. Neoplasia was detected in 25%, mainly lung and ovary, with synchronous occurrence in more than half. The response to immunosuppressive treatment was favorable in 67.8%. Eight deaths were recorded, most within the first year.
CONCLUSIONS: Anti-TIF1γ positivity identifies an inflammatory myopathy with a high oncological risk that requires early screening and close follow-up, especially in the first 3years after diagnosis.
MATERIALS AND METHODS: Retrospective study of patients with inflammatory myopathy and positive anti-TIF1γ antibodies treated at a tertiary care hospital (2012-2024). Sociodemographic variables, clinical manifestations, immunological profile, presence and type of neoplasm, treatment, and evolution were collected.
RESULTS: Twenty-eight patients were analyzed (mean age 63 years [31-88], 68% women). They were followed for a period of 5 years. Typical cutaneous manifestations predominated (61%), followed by proximal muscle weakness (61%) and dysphagia (32%), without significant pulmonary involvement. 54% presented with elevated CPK. ANA was positive in 71.4%; 57.1% presented myositis-associated antibodies and 25% other myositis-specific antibodies. Neoplasia was detected in 25%, mainly lung and ovary, with synchronous occurrence in more than half. The response to immunosuppressive treatment was favorable in 67.8%. Eight deaths were recorded, most within the first year.
CONCLUSIONS: Anti-TIF1γ positivity identifies an inflammatory myopathy with a high oncological risk that requires early screening and close follow-up, especially in the first 3years after diagnosis.